查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1190984

全球自动化止血设备市场——增长、趋势和预测 (2023-2028)

Fully Automated Coagulometer Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 117 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内，全球自动化凝血测试设备市场预计将以 8.2% 的复合年增长率增长。

主要亮点

  • 大流行的爆发影响了全自动凝血测试设备市场。 在大流行期间，血液相关疾病增加，因为许多人被确认患有 COVID-19 血液病。 例如，根据 NCBI 于 2021 年 11 月发表的一项研究，一些 COVID-19 患者会出现涉及最小血管的异常血块。 血块也可能在身体的多个部位形成，包括肺部。 这种异常的凝块会导致多种并发症，包括器官损伤、心肌梗塞和中风。
  • 因此，大流行早期血液相关疾病病例的增加加速了对全自动凝血仪的需求，这是诊断血液相关疾病的基本要求之一。 因此，预计今年市场将再次大幅增长，并有望在预测期内继续保持上升趋势。
  • 血液相关疾病负担的增加是市场的主要驱动力之一。 例如，白血病和淋巴瘤协会（LLS）在 2021 年发布的一份报告估计，美国每年大约每三分钟就会有一个人被诊断出患有白血病、淋巴瘤和骨髓瘤，估计全美共有 186,400 人。到 2021 年在美国。被诊断出患有白血病、淋巴瘤和骨髓瘤。 据估计，2021 年美国将有 34,920 人（19,320 名男性和 15,600 名女性）新诊断出患有骨髓瘤。
  • 此外，NIH 于 2022 年 4 月发表的一项研究发现，到 2020 年，团圆血症将导致 474,519 人发病和 311,594 人死亡，导致全球癌症发病率和癌症相关死亡。据估计，团聚血症是导致癌症死亡的第 15 位和第 11 位最常见原因 因此，此类案例有望推动对自动凝血仪的需求，因为它们是管理血液相关疾病的关键要求之一。
  • 创新的新产品发布预计也将推动市场增长。 例如，2021 年 10 月，Trivitron Healthcare 推出了由 Diagon Ltd. 製造的新系列凝血分析仪。 在两家公司签署合作协议后，Trivitron 与 Diagon-Vanguard Diagnostics India 宣布在印度诊断市场推出这些产品。
  • 新产品是 Diagon Hungary COAG 系列的自动/半自动 POC 系统，用于降低大手术中的出血风险以及监测止血治疗和抗凝剂的效果。 因此，此类创新可以在市场上创造新的机会并鼓励许多新进入者。 因此，预计在预测期内将出现可观的市场增长。
  • 但是，在预测期内，高昂的测试成本可能会抑制市场增长。

全自动凝血检测仪的市场趋势

医院部门预计在预测期内将显着增长

  • 医院配备了用于诊断、外科手术和改进治疗的先进技术设备。 由于血液病的诊断和手术数量不断增加，医院部门正在经历快速增长。 预计这一趋势将在预测期内继续，推动该行业的增长。
  • 随着新兴国家/地区医院数量的增加，这对全自动凝血分析仪的需求产生了积极影响。 例如，根据美国医院协会2021年年度调查，2020年全美共有超过1805家农村社区医院、3336家城市社区医院和3453家系统中的社区医院。 此外，到 2021 年，美国所有医院的住院总人数将超过 36,241,815 人。
  • 同样，根据 CCDEP（疾病动态、经济和政策中心）2021 年 4 月的报告，全国共有 25,778 家公立医院，其中公立医院最多的邦是北方邦 (4,635)、卡纳塔克邦 ( 2,842）、拉贾斯坦邦（2,850）、奥里萨邦（1,806）和西孟加拉邦。 医院凭藉其低廉的手术和药物成本以及最先进的基础设施，已成为世界领先的血液相关疾病护理中心。 医院提供从诊断到治疗再到治疗后的一贯服务，无论采用何种诊疗方式，都是患者的首选。 因此，医院数量的增加将导致患者数量的增加，这有望对该行业产生积极影响。
  • 因此，由于上述因素，该细分市场有望在预测期内实现大幅增长。

预计在预测期内北美将显着增长

  • 预计在预测期内，北美将主导整个自动化混凝剂市场。 这种增长是由血液病病例数量增加和该地区主要参与者推出新产品线等因素推动的。 例如，根据英国贫血和淋巴瘤协会 (LLS) 于 2021 年发布的一份报告，美国 2021 年估计的 1,898,160 例新癌症病例中约有 9.8% 来自贫血、淋巴瘤和骨髓瘤.据说被占用
  • 同样，根据加拿大癌症协会2022年5月发布的一份报告，2022年将有大约6700名加拿大人、4000名男性和1800人死于团圆血症。据说 因此，此类案例表明对全自动凝血检测设备的需求将会增加，这可能会推动北美地区的市场增长。
  • 主要产品的发布、市场参与者和製造商的高度集中、主要参与者之间的收购和合作以及美国血液相关疾病病例的增加是推动该国全自动凝血仪市场增长的因素。部分 例如，根据英国贫血和淋巴瘤协会（LLS）2021年发表的一份报告，在美国（US），英国贫血、淋巴瘤、骨髓瘤、骨髓增生异常综合征（MDS）、骨髓增生性肿瘤（估计有1,519,907患有 MPN 或处于缓解期的人。 另据报导，2021 年美国约有 90,390 人被诊断出患有淋巴瘤（8,830 人为霍奇金淋巴瘤，81,560 人为非霍奇金淋巴瘤）。
  • 因此，由于上述因素，所研究的市场预计将在北美地区增长。

自动凝血仪市场竞争分析

全自动血液凝固设备市场由几家主要参与者组成和整合。 公司的产品发布和战略联盟预计将推动自动化混凝剂市场的增长。 竞争格局包括 HemoSonics LLC、Siemens Healthcare、Abbott Laboratories、F. Hoffmann-La Roche Ltd、Erba Group、Werfen、Horiba、Haemonetics Corporation 和 Maccura Biotechnology，以及一些具有市场份额的知名国际和本地公司。包括分析.

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动因素
    • 血液相关疾病的负担不断增加
    • 新产品趋势
  • 市场製约因素
    • 飙升的检验成本
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模 - 百万美元）

  • 按产品类型
    • 凝血系统
    • 消耗品
    • 配饰
  • 最终用户
    • 医院
    • 诊断机构
    • 其他最终用户
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东和非洲
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章竞争格局

  • 公司简介
    • Maccura Biotechnology Co. Ltd
    • Siemens Healthcare
    • Werfen
    • Horiba
    • Haemonetics Corporation
    • HemoSonics LLC
    • F. Hoffmann-La Roche Ltd
    • Erba Group
    • Diagon
    • iLine Microsystems SL

第7章 市场机会今后动向

简介目录
Product Code: 68380

The fully automated coagulometer market is expected to register a CAGR of 8.2% over the forecast period.

Key Highlights

  • The outbreak of the pandemic impacted the fully automated coagulometer market. Blood-related diseases increased during the pandemic as many people were seen to acquire hematologic disorders along with COVID-19. For instance, as per the NCBI study published in November 2021, some people with COVID-19 develop abnormal blood clots, including in the smallest blood vessels. Clots can also form in multiple places in the body, including the lungs. This abnormal clotting can cause a variety of complications, including organ damage, heart attack, and stroke.
  • Thus, increasing cases of blood-related diseases in the initial days of the pandemic accelerated the demand for fully automated coagulometers, as it is one of the essential requirements for the diagnosis of blood-related diseases. Therefore, the market is anticipated to witness considerable growth in the current year and is expected to continue the upward trend over the forecast period.
  • The growing burden of blood-related diseases is one of the major drivers for the market. For instance, as per the report published by the Leukemia & Lymphoma Society (LLS) in 2021, approximately every three minutes, one person in United States is diagnosed with leukemia, lymphoma, or myeloma every year and an estimated combined total of 186,400 people in United States were diagnosed with leukemia, lymphoma or myeloma in 2021. The report also stated an estimated 34,920 new cases of myeloma (19,320 males and 15,600 females) were diagnosed in United States in 2021.
  • Furthermore, per the NIH study published in April 2022, leukemia was estimated to be the 15th and 11th most frequent cause of cancer incidence and cancer-related mortality globally, accounting for 474,519 incident cases and 311,594 deaths in 2020. Therefore, such instances are anticipated to propel the demand for automated coagulometers as it is one of the key requirements for managing blood-related diseases.
  • The launch of new innovative products is also anticipated to propel market growth. For instance, in October 2021, Trivitron Healthcare launched a new range of coagulation analyzer products manufactured by Diagon Ltd. Trivitron, in collaboration with Diagon-Vanguard Diagnostics India, announced the launch of these products in the Indian diagnostic market following the signing of a collaboration agreement between the companies.
  • New products include automated, semi-automated, and POC systems of the COAG series manufactured by Diagon Hungary to reduce the risk of bleeding in major surgeries and monitor the effectiveness of hemostatic therapies and anticoagulant drugs. Therefore, such innovations may create new opportunities for the market, which may encourage many new players to enter the market. Thus, considerable market growth is expected over the forecast period.
  • However, the high cost of the test is likely to restrain the market growth over the forecast period.

Fully Automated Coagulometer Market Trends

Hospital Segment Expected to Witness Considerable Growth Over the Forecast Period

  • Hospitals are well-equipped with advanced technological equipment for diagnostic and surgical procedures and improved treatments. The hospital segment is witnessing rapid growth, owing to the growing number of diagnostic and surgeries due to blood-related diseases. This trend is expected to continue over the forecast period, driving growth in the segment.
  • With the rising number of hospitals across developing countries, there is a positive impact on the demand for fully automated coagulometers. For instance, according to the American Hospital Association annual survey 2021, in United States, there were more than 1,805 rural community hospitals, 3,336 urban community hospitals, and 3,453 community hospitals in the system in 2020. Moreover, total admissions in all United States hospitals were more than 36,241,815 in 2021.
  • Similarly, as per the April 2021 report of the Center for Disease Dynamics, Economics and Policy (CCDEP), there were 25,778 public sector hospitals in the country, and the states with the highest number of public hospitals were Uttar Pradesh (4,635), Karnataka (2,842), Rajasthan (2,850), Odisha (1,806), and West Bengal. Hospitals are the major treatment centers for blood-related diseases globally, owing to the low cost of surgeries and medication and the availability of state-of-art infrastructure. Hospitals offer integrated services from diagnostics to treatment and treatment to post-treatment, which is patients' first choice for any diagnostic and treatment procedure. Thus increasing the number of hospitals may increase the number of patients, which is expected to positively impact the segment.
  • Therefore, owing to the abovementioned factors, the segment is anticipated to witness considerable growth over the forecast period.

North America Expected to Witness Significant Growth Over the Forecast Period

  • North America is expected to dominate the overall fully automated coagulometer market over the forecast period. The growth is due to factors such as the rising cases of blood-related diseases and the launch of new product lines by the key players in the region. For instance, as per the report published by the Leukemia & Lymphoma Society (LLS) in 2021, new cases of leukemia, lymphoma, and myeloma accounted for around 9.8% of the estimated 1,898,160 new cancer cases in United States in 2021.
  • Similarly, as per the report published by the Canadian Cancer Society in May 2022, around 6,700 Canadians will be diagnosed with leukemia, 4,000 men will be diagnosed with leukemia, and 1,800 will die from it in 2022. Therefore, such instances indicate that the demand for fully automated coagulometers may increase, thereby propelling the market growth in the North American region.
  • Key product launches, high concentration of market players or manufacturer's presence, acquisition and & partnerships among major players, and rising cases of blood-related diseases in United States are some of the factors driving the growth of the fully automated coagulometer market in the country. For instance, as per the report published by the Leukemia & Lymphoma Society (LLS) in 2021, an estimated 1,519,907 people in United States (US) were living with or in remission from leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPNs) in 2021. The report also stated that around 90,390 people in United States were diagnosed with lymphoma in 2021 (8,830 cases of Hodgkin Lymphoma and 81,560 cases of Non-Hodgkin Lymphoma).
  • Therefore, owing to the aforesaid factors, the growth of the studied market is anticipated in the North America Region.

Fully Automated Coagulometer Market Competitive Analysis

The fully automated coagulometer market is consolidated and consists of a few major players. Product launches and strategic alliances by companies are expected to drive the fully automated coagulometer market growth. The competitive landscape includes an analysis of a few international as well as local companies which hold market shares and are well known, including HemoSonics LLC, Siemens Healthcare, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Erba Group, Werfen, Horiba, Haemonetics Corporation, and Maccura Biotechnology Co. Ltd, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Defination
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Blood Related Diseases
    • 4.2.2 Emerging Trends in Product
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Test
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Product Type
    • 5.1.1 Coagulation System
    • 5.1.2 Consumables
    • 5.1.3 Accessories
  • 5.2 By End User
    • 5.2.1 Hospitals
    • 5.2.2 Diagnostic Laboratories
    • 5.2.3 Other End Users
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Maccura Biotechnology Co. Ltd
    • 6.1.2 Siemens Healthcare
    • 6.1.3 Werfen
    • 6.1.4 Horiba
    • 6.1.5 Haemonetics Corporation
    • 6.1.6 HemoSonics LLC
    • 6.1.7 F. Hoffmann-La Roche Ltd
    • 6.1.8 Erba Group
    • 6.1.9 Diagon
    • 6.1.10 iLine Microsystems SL

7 MARKET OPPORTUNITIES AND FUTURE TRENDS